Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Funding, Epidemiology And Balanced Policies To Fuel India Growth - CII Lifescience Conclave

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Establishment of a new global disease detection center for epidemiology studies in India, a unique government funding method to boost innovation, and academic partnerships were among the prominent discussion topics at the Annual LifeScience Conclave, organized by the Confederation of Indian Industry in the capital city

You may also be interested in...



WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit

MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel